作者
Abbas Walji,Eric D. Hostetler,Harold G. Selnick,Zhizhen Zeng,Patricia Miller,Idriss Bennacef,Cristian Salinas,Brett Connolly,Liza Gantert,Marie A. Holahan,Stacey O’Malley,Mona Purcell,Kerry Riffel,Jing Li,Jaume Balsells,Julie A. O’Brien,Stacey Melquist,Aileen Soriano,Xiaoping Zhang,Aimie M. Ogawa,Serena Xu,Elizabeth Joshi,Joseph Della Rocca,Fred Hess,Joel B. Schachter,David Hesk,David Schenk,Arie Struyk,Kerim Babaoglu,Talakad G. Lohith,Yaode Wang,Kun Yang,Jianmin Fu,Jeffrey L. Evelhoch,Paul J. Coleman
摘要
Neurofibrillary tangles (NFTs) made up of aggregated tau protein have been identified as the pathologic hallmark of several neurodegenerative diseases including Alzheimer's disease. In vivo detection of NFTs using PET imaging represents a unique opportunity to develop a pharmacodynamic tool to accelerate the discovery of new disease modifying therapeutics targeting tau pathology. Herein, we present the discovery of 6-(fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine, 6 ([(18)F]-MK-6240), as a novel PET tracer for detecting NFTs. 6 exhibits high specificity and selectivity for binding to NFTs, with suitable physicochemical properties and in vivo pharmacokinetics.